Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

US National Institutes of Health (NIH) grant open #PAR-25-095

Response due Sep 07, 2026 · 00:00 UTC

Summary

This NIH funding opportunity (PAR-25-095) invites R01 research grant applications for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. Clinical trials are explicitly not allowed under this mechanism. The opportunity is issued by the National Institutes of Health (HHS) and is open for applications from November 2024 through September 2026.

What they want

Applicants are invited to conduct secondary analyses and integration of existing data sources to advance understanding of cancer risk factors and related health outcomes. Clinical trials are excluded from this funding opportunity. Research must leverage pre-existing datasets rather than collecting new primary data.

Technical requirements

Secondary analysis of existing data only — no new primary data collection
Clinical trials are not allowed under this mechanism
Must conform to NIH R01 grant application requirements

How they evaluate

Submission: Grants.gov federal grants portal (PAR-25-095)

Risks & flags

No dollar values or award sizes disclosed in the opportunity text
Very long open window (Nov 2024 – Sep 2026) typical of NIH program announcements with multiple submission cycles — not a wired sole-source indicator, but budgets and scoring criteria are entirely unstated here

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Secondary Analysis and Integration of Exis…

Due Sep 07

Onboard ↗